Aberdeen, UK – 9 June 2016 – NovaBiotics Ltd (“NovaBiotics” or the “Company”), the Aberdeen-based clinical-stage biotechnology company, announces today that three sets of new data will be presented at this year’s European Cystic Fibrosis (CF) Society Conference, taking place in Basel, Switzerland between 8-11 June.
The posters are focused on NovaBiotics’ first-in-class orphan drug candidate Lynovex® (cysteamine), a novel, highly differentiated therapy for the treatment of CF-associated lung disease and Novamycin®, the Company’s first in class antifungal peptide being developed to target life threatening infections, including respiratory fungal infections associated with CF and respiratory aspergillosis.
The presenters are Dr Douglas Fraser-Pitt, Principal Scientist and Research Associates Dan Smith and Dr Laura Katvars at NovaBiotics.
The details of the posters are as follows:
Title: Cysteamine as a strategy against Burkholderia cepacia complex
Poster number: ePS06.2
Presenter: Dan Smith
Date: 9 June 2016
Location: ePoster Corner A
Time: 14.00-15.00
Title: Novel approaches for cystic fibrosis associated respiratory fungal infections
Poster number: ePS03.9
Presenter: Dr Laura Katvars
Date: 9 June 2016
Location: ePoster Corner A
Time: 14.00–15.00
Title: Inhaled cysteamine for the chronic management and symptomatic control of cystic fibrosis associated lung disease
Poster number: ePS03.5
Presenter: Dr Douglas Fraser-Pitt, Principal Scientist, NovaBiotics
Date: 10 June 2016
Location: ePoster Corner A
Time: 14.00 – 15.00
The posters are focused on NovaBiotics’ first-in-class orphan drug candidate Lynovex® (cysteamine), a novel, highly differentiated therapy for the treatment of CF-associated lung disease and Novamycin®, the Company’s first in class antifungal peptide being developed to target life threatening infections, including respiratory fungal infections associated with CF and respiratory aspergillosis.
The presenters are Dr Douglas Fraser-Pitt, Principal Scientist and Research Associates Dan Smith and Dr Laura Katvars at NovaBiotics.
The details of the posters are as follows:
Title: Cysteamine as a strategy against Burkholderia cepacia complex
Poster number: ePS06.2
Presenter: Dan Smith
Date: 9 June 2016
Location: ePoster Corner A
Time: 14.00-15.00
Title: Novel approaches for cystic fibrosis associated respiratory fungal infections
Poster number: ePS03.9
Presenter: Dr Laura Katvars
Date: 9 June 2016
Location: ePoster Corner A
Time: 14.00–15.00
Title: Inhaled cysteamine for the chronic management and symptomatic control of cystic fibrosis associated lung disease
Poster number: ePS03.5
Presenter: Dr Douglas Fraser-Pitt, Principal Scientist, NovaBiotics
Date: 10 June 2016
Location: ePoster Corner A
Time: 14.00 – 15.00
